Today, Cambrex announced its stability storage business, Q1 Scientific, and opened a new cGMP facility in Durham, North Carolina, expanding its capacity for environmentally controlled stability storage services to North America's pharmaceutical, medical device, and life sciences industries.
CDMO Serán BioScience recently announced that it has completed an expansion to increase the number of process manufacturing suites at its facility in Bend, Oregon, from 6 to 14, adding approximately 130% more cGMP clinical manufacturing capacity.
Catalent has opened a new commercial-scale cell therapy manufacturing facility at its European center of excellence for cell therapies in Gosselies, Belgium.
US CDMO Cambrex has agreed to buy Snapdragon Chemistry, a compatriot company specializing in developing continuous flow and batch processes for APIs. Snapdragon is based in Waltham, Massachusetts, where it employs 74 people.
UK specialist healthcare investor GHO Capital Partners and US investment firm The Vistria Group have entered into an agreement to buy a controlling interest in US CDMO Alcami from current private equity owners Madison Dearborn Partners (MDP) and Ampersand Capital Partners. Financial terms of the deal were not disclosed.
Ariceum Therapeutics, a Berlin-headquartered private biotech developing radiopharmaceutical products for the diagnosis and systemic targeted certain hard-to-treat cancers, and AmbioPharm, a globally oriented US CDMO specialized in peptides, have agreed a strategic partnership in peptide conjugates.
Swedish multinational CDMO Recipharm has bolstered its sterile filling capabilities at its facility in Kaysersberg, France, by installing Lab+ continuous automated technology.
Catalent has announced a $12 million expansion program to increase biologics CGMP analytical capabilities at its flagship facility in Kansas City, Missouri.
German CDMO Evotec is to acquire compatriot company Central Glass Germany from Japanese owner Central Glass for a nominal price of €1. The transaction, which remains subject to the usual closing conditions, is expected to complete on Nov. 1.
